Comparative efficacy and safety of first-line treatments for RAS wild-type metastatic colorectal cancer: A systematic review and network meta-analysis
Songke Wu, Chengshi Wang, Shuyun Liu · 2026
Read Comparative efficacy and safety of first-line treatments for RAS wild-type metastatic colorectal cancer: A systematic review and network meta-analysis by Songke Wu, Chengshi Wang, Shuyun Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13266398.txt.
Description
Songke Wu, Chengshi Wang, and Shuyun Liu compare first treatments for metastatic bowel cancer without RAS mutations, in a 2026 network meta-analysis. Many targeted regimens exist without head-to-head trials for all pairs. Fifteen randomised trials with about six thousand patients formed the network. Survival, response, and safety were ranked.
Two antibody-plus-chemotherapy regimens beat a third comparator on overall survival. The cetuximab combination ranked highest for survival and time without progression. Benefit concentrated in left-sided tumours, with none seen for right-sided disease. Severe side effects were more frequent with the winning class. Tumour side should guide first choice.
Catalog record
| CREATOR | Songke Wu, Chengshi Wang, Shuyun Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |